Hormone Refractory Prostate Cancer $Hormone Refractory Prostate Cancer RSS feed$ This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

669 records returned

Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hormone refractoriness is a lethal event for advanced prostate cancer patients, but the mechanisms of the disease are not well elucidated, especially for the so-called "outlaw" pathways of androgen receptor (AR)-dependent, androgen-independent hormone-refractory prostate cancer.Androgen-dependent prostate cancer LNCaP cells were treated with bicalutamide under an androgen-depleted condition to obtain refractory cells. In the obtained cell line, LNCaP-CS10, we analyzed the effects of androgen and bicalutamide on cell growth and prostate-specific antigen (PSA) production. In addition, AR gene mutation, AR expression levels, ...
Source: The Prostate - November 10, 2009 Category: Urology & Nephrology Authors: Nobuyuki Ishikura, Hiromitsu Kawata, Ayako Nishimoto, Ryo Nakamura, Nobuya Ishii, Yuko Aoki Source Type: journals

Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The PSA to FT ratio is the growing rate parameter expressing different biology patterns and assessing different groups of prostate cancer patients. In our opinion, the results of the present study might have wide applications in understanding, assessing and planning prostate cancer studies including basic science, screening, assessing risk of the disease, predicting disease stage as well natural history after a planned treatment involving biochemical recurrence, progression, hormone refractory prostate cancer and disease-specific survival. Content Type Journal ArticleCategory Urology - Ori...
Source: International Urology and Nephrology - November 9, 2009 Category: Urology & Nephrology Tags: International Urology and Nephrology Source Type: journals

Clusterin (CLU) and prostate cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The role of clusterin (CLU) in prostate tumorigenesis is probably the most highly controversial, with evidence that CLU expression is increased or decreased in different cancer models. For example, some studies showed that CLU expression is increased in advanced stages of prostate cancer and that suppression of CLU expression sensitizes prostate cancer cells to chemotherapeutic drugs killing. In contrast with the hypothesis that CLU is a positive modulator of prostate cancer, we and others have observed that CLU is downregulated during human prostate cancer progression. Accordingly, a meta-analysis of available microar...
Source: Advances in Cancer Research - November 4, 2009 Category: Cancer & Oncology Authors: Rizzi F, Bettuzzi S Tags: Adv Cancer Res Source Type: journals

VadimezanEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tumor cells rely on the existence of a specialized vasculature for the oxygen and nutrients that they require in order to grow and survive. Targeting the tumor vasculature as a technique for inhibiting tumor growth was first attempted with angiogenesis inhibitors, a class of drugs that compromise the formation of new blood vessels. More recently a new class of drugs called vascular disrupting agents (VDAs) has been reported. Rather than preventing the formation of new blood vessels, VDAs target endothelial cells and pericytes in the already-established vascular network supporting the tumor. VDAs are designed to induce mass...
Source: Prous Science - Molecule of the Month - October 30, 2009 Category: Chemistry Source Type: info

Critical Role Of The Bone Microenvironment In Cancer Metastases - Treating Bone Metastases In Prostate Cancer PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
UroToday.com - Most men with advanced, hormone refractory prostate cancer have metastases which occur preferentially in the skeleton (1). Why is this bad? Bone metastases are incurable and cause skeletal-related events (SREs) that contribute substantial morbidity: fractures, nerve compression, and severe bone pain. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 26, 2009 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

TNF-blockade in patients with advanced hormone refractory prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory SHORT REPORTDOI 10.1007/s10637-009-9346-1Authors Luis A. Diaz, The Ludwig Center for Cancer Genetics & Therapeutics at Johns Hopkins Baltimore MD 21231 USAWells Messersmith, University of Colorado Cancer Center Division of Medical Oncology Aurora CO 80045 USALori Sokoll, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Department of Oncology Baltimore MD 21231 USAVicki Sinibaldi, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Department of Oncology Baltimore MD 21231 USASandy Moore, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Department of Oncology Baltim...
Source: Investigational New Drugs - October 21, 2009 Category: Drugs & Pharmacology Tags: Investigational New Drugs Source Type: journals

A Novel Experimental Heme Oxygenase-1-Targeted Therapy for Hormone-Refractory Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Heme oxygenase-1 (HO-1), a member of the heat shock protein family, plays a key role as a sensor and regulator of oxidative stress. Herein, we identify HO-1 as a biomarker and potential therapeutic target for advanced prostate cancer (PCA). Immunohistochemical analysis of prostate tissue using a progression tissue microarray from patients with localized PCA and across several stages of disease progression revealed a significant elevation of HO-1 expression in cancer epithelial cells, but not in surrounding stromal cells, from hormone-refractory PCA (HRPCA) compared with hormone-responsive PCA and benign tissue. Silencing t...
Source: Cancer Research - October 15, 2009 Category: Cancer & Oncology Authors: Alaoui-Jamali, M. A., Bismar, T. A., Gupta, A., Szarek, W. A., Su, J., Song, W., Xu, Y., Xu, B., Liu, G., Vlahakis, J. Z., Roman, G., Jiao, J., Schipper, H. M. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Androgen-independent prostate carcinoma (AICP) is one of the tumors that continue to respond poorly to chemotherapy. Recently, protocols based on the use of docetaxel have significantly improved survival for patients in this disease. In other types of neoplastic disease, combined therapy with taxanes and anthracycline derivatives has been shown to produce additive effects in terms of growth inhibition, and superior tolerability when associated with weekly administration schedules. These findings prompted us to examine the tolerability and efficacy of weekly treatment of AICP with docetaxel (DOX) plus epirubicin (EPI). ...
Source: Oncology Research - October 9, 2009 Category: Cancer & Oncology Authors: Neri B, Molinara E, Pantaleo P, Rangan S, Crisci A, Della Melina A, Raugei A, Villari D, Nicitat G Tags: Oncol Res Source Type: journals

A Novel Experimental Heme Oxygenase-1-Targeted Therapy for Hormone-Refractory Prostate Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Heme oxygenase-1 (HO-1), a member of the heat shock protein family, plays a key role as a sensor and regulator of oxidative stress. Herein, we identify HO-1 as a biomarker and potential therapeutic target for advanced prostate cancer (PCA). Immunohistochemical analysis of prostate tissue using a progression tissue microarray from patients with localized PCA and across several stages of disease progression revealed a significant elevation of HO-1 expression in cancer epithelial cells, but not in surrounding stromal cells, from hormone-refractory PCA (HRPCA) compared with hormone-responsive PCA and benign tissue. Silenci...
Source: Cell Research - October 5, 2009 Category: Cytology Authors: Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM Tags: Cancer Res Source Type: journals

Oncoforum Urology: Prostate Cancer 2008 at a GlanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Many interesting new data on PCa were presented at the 2008 oncological and urological congresses. Some may have an impact on clinical practice, whereas other data raise new questions that will have to be answered by further research.Take Home Message: This paper discusses interesting new data on prostate cancer (PCa) presented at 2008 urological and oncological congresses. These data cover diagnosis and staging, localised PCa, locally advanced PCa and hormone-refractory PCa and may have an impact on current or future clinical practice. (Source: European Urology Supplements)
Source: European Urology Supplements - October 4, 2009 Category: Urology & Nephrology Authors: Nicolas Mottet Source Type: journals

Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic ProfilingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study aimed to identify novel therapeutic targets and predictive biomarkers of Docetaxel resistance in HRPC. We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Functional validation experiments were performed using recombinant protein treatment and siRNA knockdown experiments. Serum/plasma levels of the targets in patient samples were measured by ELISA. The IC50 for Docetaxel in the PC3-Rx cells was 13-fold greater than the parent PC-3 cell ...
Source: Cancer Research - October 1, 2009 Category: Cancer & Oncology Authors: Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W., Breit, S. N., Sutherland, R. L., Henshall, S. M., Horvath, L. G. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: A more rapid rate of PSA decline (PSAHL <70 days) measured after 4 cycles of chemotherapy was associated with a longer OS. This result was independent of other known markers of survival and allowed for a greater survival differentiation than PSA response. PMID: 19829727 [PubMed - as supplied by publisher] (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - September 30, 2009 Category: Urology & Nephrology Authors: Hanninen M, Venner P, North S Tags: Can Urol Assoc J Source Type: journals

The biology of hormone refractory breast and prostate cancer: An NCI workshop report.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The molecular regulation of growth and progression of hormone refractory breast and prostate cancers remains challenging. The Division of Cancer Biology, NCI organized a small "think tank" style workshop and invited scientists in relevant areas to assess the state of science on the biology of hormone refractory tumors and to identify potential research opportunities to enhance a better understanding of the molecular regulation of these tumors. The meeting, held on May 27-29, 2008 in Bethesda, MD, was co-chaired by Drs. Michael Geoffrey Rosenfeld and Michael Press. While expression of estrogen or progesterone receptors ...
Source: Cancer Biology and Therapy - September 29, 2009 Category: Cancer & Oncology Authors: Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG, Nelson P Tags: Cancer Biol Ther Source Type: journals

Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The efficacy of current therapy for hormone-refractory prostate cancer is still unsatisfactory and new agents and therapeutic modalities are needed. The aims of the present work were to examine the in vitro activity and mechanisms of action of different antitumor drug combinations in hormone-resistant prostate cancer (HRPC) cell lines.The activity of docetaxel (Doc), cisplatin (Cis), oxaliplatin (Oxa), SN-38 and ST1481, singly or in combination, was assessed in different HRPC cell lines (PC3, parental DU145 and taxane-resistant DU145-R) by SRB test. Apoptosis was evaluated by TUNEL and ANN-V assays. Extrusion pump activity...
Source: The Prostate - September 28, 2009 Category: Urology & Nephrology Authors: Francesco Fabbri, Giovanni Brigliadori, Silvia Carloni, Paola Ulivi, Anna Tesei, Rosella Silvestrini, Dino Amadori, Wainer Zoli Source Type: journals

aPKC{lambda}/{iota} promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 [Medical_Sciences]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Understanding the mechanism by which hormone refractory prostate cancer (HRPC) develops remains a major issue. Alterations in HRPC include androgen... (Source: Proceedings of the National Academy of Sciences)
Source: Proceedings of the National Academy of Sciences - September 21, 2009 Category: Science Authors: Ishiguro, H., Akimoto, K., Nagashima, Y., Kojima, Y., Sasaki, T., Ishiguro-Imagawa, Y., Nakaigawa, N., Ohno, S., Kubota, Y., Uemura, H. Tags: Medical_Sciences Source Type: journals

Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Resveratrol is a dietary polyphenol espoused to have chemopreventive activity against a variety of human cancer types. We first reported that resveratrol significantly decreases the proliferation of both androgen-dependent and hormone-refractory prostate cancer cells. However, the effects of resveratrol in normal prostate epithelial and stromal cells, particularly with regard to its uptake, subcellular distribution and intracellular targets, have not been investigated. To advance the knowledge on accessibility and cellular disposition of resveratrol in prostate cells, [(3)H] resveratrol, fractionation of cell extracts ...
Source: Asian Journal of Andrology - September 20, 2009 Category: Urology & Nephrology Authors: Hsieh TC Tags: Asian J Androl Source Type: journals

Reports From Duke University Describe Recent Advances In Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
"The impact of ligand binding on nuclear receptor (NR) structure and the ability of target cells to distinguish between different receptor-ligand complexes are key determinants of the pharmacological activity of NR ligands. However, until relatively recently, these mechanistic insights have not been used in a prospective manner to develop screens for NR modulators with specific therapeutic activities," investigators in the United States report. "Driven by the need for unique androgen receptor (AR) antagonists that retain activity in hormone-refractory prostate cancer, we developed and applied a conformation-based screen to...
Source: Cancercompass News: Prostate Cancer - September 17, 2009 Category: Cancer & Oncology Source Type: news

Ets-1 and hypoxia inducible factor-1[alpha] inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study suggests that AT1R blockade may have a significant impact on HRPC through the inhibition of HIF-1[alpha] and Ets-1 and the resulting suppression of angiogenesis. Our results provide the molecular basis of the clinical benefit of ARB as an angiogenic inhibitor in HRPC. Prostate © 2009 Wiley-Liss, Inc. (Source: The Prostate)
Source: The Prostate - September 16, 2009 Category: Urology & Nephrology Authors: Takeo Kosaka, Akira Miyajima, Suguru Shirotake, Eiji Kikuchi, Masanori Hasegawa, Shuji Mikami, Mototsugu Oya Source Type: journals

The Neuroendocrine-Derived Peptide Parathyroid Hormone-Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen ReceptorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we show that neuroendocrine-derived parathyroid hormone–related protein (PTHrP)–mediated signaling through the epidermal growth factor receptor (EGFR) and Src pathways contributes to the phenotype of advanced prostate cancer by reducing AR protein turnover. PTHrP-induced accumulation of AR depended on the activity of Src and EGFR and consequent phosphorylation of the AR on Tyr534. PTHrP-induced tyrosine phosphorylation of AR resulted in reduced AR ubiquitination and interaction with the ubiquitin ligase COOH terminus of Hsp70-interacting protein. These events result in increased accumulation of A...
Source: Cancer Research - September 13, 2009 Category: Cancer & Oncology Authors: DaSilva, J., Gioeli, D., Weber, M. J., Parsons, S. J. Tags: Molecular Biology, Pathobiology, and Genetics Source Type: journals

Global levels of histone modifications predict prostate cancer recurrenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Epigenetic alterations such as DNA methylation and histone modifications play important roles in carcinogenesis. It was reported that global histone modification patterns are predictors of cancer recurrence in various tumor entities. Our study was performed to evaluate histone lysine (HxKy) and histone acetyl (HxAc) modifications in prostate tissue.A tissue microarray with 113 prostate cancer (PCA), 23 non-malignant prostate tissues was stained with antibodies against H3K4 mono-(H3K4me1), di-(H3K4me2), tri-(H3K4me3) methylation, H3K9me1, H3K9me2, H3K9me3, H3 and H4 pan-acetylation (H3Ac, H4Ac). We also analyzed H3K4 methyl...
Source: The Prostate - September 7, 2009 Category: Urology & Nephrology Authors: Jörg Ellinger, Philip Kahl, Johannes von der Gathen, Sebastian Rogenhofer, Lukas C. Heukamp, Ines Gütgemann, Bernhard Walter, Ferdinand Hofstädter, Reinhard Büttner, Stefan C. Müller, Patrick J. Bastian, Alexander von Ruecker Source Type: journals

Bayer And Algeta Enter Global Agreement For Development And Commercialization Of Treatment For Bone Metastases In Cancer PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bayer Schering Pharma AG, Germany has entered into a global agreement with Algeta ASA, Oslo, Norway for the development and commercialization of Alpharadin, a novel alpha-emitting radiopharmaceutical, based on radium-223. Alpharadin is currently being evaluated in a global Phase III trial for the treatment of bone metastases in symptomatic hormone-refractory prostate cancer (HRPC) patients. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 3, 2009 Category: Pharmaceuticals Source Type: news

Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These results underscore the ability of docetaxel to induce concomitantly caspase-dependent and independent death pathways in prostate cancer cells. The results also point to LEDGF/p75 as a potential contributor to cellular resistance to docetaxel-induced lysosomal destabilization and cell death, and an attractive candidate for molecular targeting in HRPC. (Source: Molecular Cancer)
Source: Molecular Cancer - August 27, 2009 Category: Cancer & Oncology Authors: Melanie Mediavilla-VarelaFabio PachecoFrankis AlmaguelJossymar PerezEva SahakianTracy DanielsLai LeohAmelia PadillaNathan WallMichael LillyMarino De LeonCarlos Casiano Source Type: journals

The Neuroendocrine-Derived Peptide Parathyroid Hormone-Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we show that neuroendocrine-derived parathyroid hormone-related protein (PTHrP)-mediated signaling through the epidermal growth factor receptor (EGFR) and Src pathways contributes to the phenotype of advanced prostate cancer by reducing AR protein turnover. PTHrP-induced accumulation of AR depended on the activity of Src and EGFR and consequent phosphorylation of the AR on Tyr(534). PTHrP-induced tyrosine phosphorylation of AR resulted in reduced AR ubiquitination and interaction with the ubiquitin ligase COOH terminus of Hsp70-interacting protein. These events result in increased accumulation of AR and thus...
Source: Cell Research - August 24, 2009 Category: Cytology Authors: Dasilva J, Gioeli D, Weber MJ, Parsons SJ Tags: Cancer Res Source Type: journals

Pathological Effects of Prostate Cancer Correlate With Neuroendocrine Differentiation and PTEN Expression After Bicalutamide MonotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: PTEN inactivation and neuroendocrine differentiation were related to refractoriness to bicalutamide therapy. These results support the hypothesis that neuroendocrine differentiation is caused by activation of the serine threonine kinase Akt pathway, which results from PTEN inactivation. (Source: The Journal of Urology)
Source: The Journal of Urology - August 13, 2009 Category: Urology & Nephrology Authors: Won Sik Ham, Nam Hoon Cho, Won Tae Kim, Hee Jeong Ju, Jin Sun Lee, Young Deuk Choi Tags: Oncology: Prostate/Testis/Penis/Urethra Source Type: journals

Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite an excellent initial response to first-line hormonal treatment, most patients with metastatic prostate cancer will succumb to a hormone-refractory form of the disease. Because these tumors are still dependent on a functional androgen receptor (AR), there is a need to find novel and more potent antiandrogens. While searching for small molecules that bind to the AR and inhibit its transcriptional activity, BMS-641988 was discovered. This novel antiandrogen showed an increased (>1 log) potency compared with the standard antiandrogen, bicalutamide, in both binding affinity to the AR and inhibition of AR-mediated tra...
Source: Cancer Research - August 11, 2009 Category: Cancer & Oncology Authors: Attar, R. M., Jure-Kunkel, M., Balog, A., Cvijic, M. E., Dell-John, J., Rizzo, C. A., Schweizer, L., Spires, T. E., Platero, J. S., Obermeier, M., Shan, W., Salvati, M. E., Foster, W. R., Dinchuk, J., Chen, S.-J., Vite, G., Kramer, R., Gottardis, M. M. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion NTx, a potent collagenous marker of bone resorption, along with the novel NTx/PINP ratio provide useful cut-off values for identifying a group of patients suffering from painful osseous metastases from hormone-refractory prostatic carcinoma who do not respond to palliative treatment with 186Re-HEDP. This information could help avoid an inefficient and expensive radionuclide treatment. Also, in the cohort of patients who will eventually undergo such treatment, the medium-term posttreatment changes in NTx offer valuable predictive information regarding long-term palliative response. Content T...
Source: European Journal of Nuclear Medicine and Molecular Imaging - August 7, 2009 Category: Radiology Tags: European Journal of Nuclear Medicine and Molecular Imaging Source Type: journals

Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite an excellent initial response to first-line hormonal treatment, most patients with metastatic prostate cancer will succumb to a hormone-refractory form of the disease. Because these tumors are still dependent on a functional androgen receptor (AR), there is a need to find novel and more potent antiandrogens. While searching for small molecules that bind to the AR and inhibit its transcriptional activity, BMS-641988 was discovered. This novel antiandrogen showed an increased (>1 log) potency compared with the standard antiandrogen, bicalutamide, in both binding affinity to the AR and inhibition of AR-mediated...
Source: Cell Research - August 3, 2009 Category: Cytology Authors: Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M, Shan W, Salvati ME, Foster WR, Dinchuk J, Chen SJ, Vite G, Kramer R, Gottardis MM Tags: Cancer Res Source Type: journals

A case of indirect cauda equina syndrome from metastatic prostate cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the case of a patient with metastatic hormone refractory prostate cancer in whom "indirect" cauda equina syndrome developed concurrent with multilevel spinal cord compression (SCC). Three months after his first positive bone scan, a 65-year-old otherwise healthy man presented with severe back pain, bilateral lower extremity paresthesias, leg weakness and urinary retention. Magnetic resonance imaging (MRI) showed a dural-based mass causing SCC at the T9, T10 and T11 vertebrae, with a normal cauda equina. He received corticosteroids and palliative external beam radiotherapy, resulting in good pain control and gradu...
Source: Canadian Urological Association Journal - July 31, 2009 Category: Urology & Nephrology Authors: Lefresne S, Fairchild A, Bistritz A, Venner P, Yee D Tags: Can Urol Assoc J Source Type: journals

A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The incidence of, and mortality from, prostate cancer (PCa) has increased in Asian countries over the past decades, partly due to a change in dietary habits. Recent reports have revealed differences in the molecular basis of PCa among people of differing racial or ethnic backgrounds. PCa xenograft models established from Asian patients would be useful for understanding the basis of PCa in Asian populations; we therefore established and characterized a novel PCa xenograft model, JDCaP, from a metastatic skin lesion of a Japanese hormone-refractory prostate cancer (HRPC) patient.Skin metastatic tissue derived from poorly dif...
Source: The Prostate - July 29, 2009 Category: Urology & Nephrology Authors: Takahiro Kimura, Hiroshi Kiyota, Daisuke Nakata, Tsuneo Masaki, Masami Kusaka, Shin Egawa Source Type: journals

Surveyed Oncologists Expect To Prescribe Provenge To About Half Of Their Prostate Cancer Patients If The Vaccine Is ApprovedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon's Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 29, 2009 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Driven By Launch Of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase By $2B Through 2018Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic hormone-refractory population, most notably Dendreon's Provenge. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 27, 2009 Category: Pharmaceuticals Source Type: news

Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Metronomic CTX plus CXB and DEX showed favorable toxicity and activity profile in patients. VE-C gene expression and VEGF levels represent potentially useful pharmacodynamic markers for the clinical response. PMID: 19622584 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 20, 2009 Category: Cancer & Oncology Authors: Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G Tags: Clin Cancer Res Source Type: journals

Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: Predictive factorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Objectives: To determine the optimal cut-off of a nadir prostate-specific antigen (PSA) for prediction of progression within 24 months after combined androgen blockade (CAB) and to analyze predictive factors of failing to achieve the nadir PSA.Methods: We retrospectively reviewed the medical records of 343 patients with prostate cancer treated with CAB from 2000 to 2005. We determined the nadir PSA level that predicts progression to hormone refractory prostate cancer (HRPC) at 24 months after CAB. Predictive factors for failing to achieve a determined nadir PSA were analyzed.Results: Mean age was 74.0 years. Mean follow ...
Source: International Journal of Urology - July 13, 2009 Category: Urology & Nephrology Authors: Seung Chol Park, Joung Sik Rim, Han Yong Choi, Choung Soo Kim, Sung Joon Hong, Wun Jae Kim, Sang Eun Lee, Jae Mann Song, Jin Han Yoon Source Type: journals

Treatment of Painful Bone Metastases in Hormone-Refractory Prostate Cancer with Zoledronic Acid and Samarium-153-Ethylenediaminetetramethylphosphonic Acid CombinedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Palliative Medicine Jul 2009, Vol. 12, No. 7: 649-651. (Source: Journal of Palliative Medicine)
Source: Journal of Palliative Medicine - July 13, 2009 Category: Palliative Care Tags: article Source Type: journals

Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Docetaxel plus estramustine chemotherapy represents an active and well tolerated treatment for Japanese HRPC patients. (Source: International Journal of Urology)
Source: International Journal of Urology - July 7, 2009 Category: Urology & Nephrology Authors: Akihiro Matsumoto, Atsushi Inoue, Satoshi Yokoi, Kazuyoshi Nozumi, Kanetaka Miyazaki, Shigeru Hosoki, Maki Nagata, Kunio Yamaguchi Source Type: journals

Hormone Therapy for Prostate Cancer: Exploring Current ControversiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Neoadjuvant or adjuvant hormone therapy with radical treatment may improve survival in carefully selected patients with PCa. Intermittent hormone therapy seems to reduce adverse events and improve QoL without a negative effect on survival. The availability of different formulations of a luteinising hormone-releasing hormone agonist offers patients an individualised treatment approach.Take Home Message: Hormone therapy is beneficial in carefully selected prostate cancer patients; however, patients’ preferences should be taken into consideration in the treatment decision-making process. (Source: European Urology Supplements)
Source: European Urology Supplements - July 7, 2009 Category: Urology & Nephrology Authors: Francesco Montorsi, Richard Berges, Jacques Irani, Claude C. Schulman Source Type: journals

Celastrol Potentiates Radiotherapy by Impairment of DNA Damage Processing in Human Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Celastrol sensitized PC-3 cells to radiation both in vitro and in vivo by impairing DNA damage processing and augmenting apoptosis. Celastrol might represent a promising new adjuvant regimen for the treatment of hormone-refractory prostate cancer. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - June 25, 2009 Category: Radiology Authors: Yao Dai, Jeffrey T. DeSano, Yang Meng, Qing Ji, Mats Ljungman, Theodore S. Lawrence, Liang Xu Tags: Biology Contributions Source Type: journals

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Simultaneous knock down of the IAPs not only sensitised the PC-3 to TRAIL but also inhibited their proliferation rates and clonogenic survival. The inability to alter sensitivity to other triggers of apoptosis suggests that this effect is specific for death receptor pathways and knock down might facilitate immune-surveillance mechanisms to counter cancer progression and, in combination with therapeutic approaches using TRAIL, could represent an important treatment strategy. (Source: Molecular Cancer)
Source: Molecular Cancer - June 22, 2009 Category: Cancer & Oncology Authors: Catherine GillCatherine DowlingAmanda O'NeillR. William Watson Source Type: journals

Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There is currently no successful therapy for androgen-independent prostate cancer. Ursolic acid (UA), a pentacyclic triterpenoid compound, has been shown to have an anti-proliferative effect on various tumors. We investigated the effect of UA on cell viability in the human hormone-refractory prostate cancer cell line DU-145, as well as the molecular mechanisms underlying its growth inhibiting effect. We demonstrated that UA induces apoptosis and the activation of caspase-3 in DU145 cells. UA also causes the activation of c-Jun N-terminal kinase (JNK), but has no effect on extracellular signal-regulated protein kinases ...
Source: Biochimie - June 18, 2009 Category: Biochemistry Authors: Zhang YX, Kong CZ, Wang HQ, Wang LH, Xu CL, Sun YH Tags: Biochimie Source Type: journals

18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Lesions detected with 18F-choline PET/CT are frequently measurable by RECIST at baseline. Therefore, it may be feasible to include comparisons to RECIST in evaluations of 18F-choline as a therapeutic response marker for hormone refractory prostate cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s12149-009-0273-1Authors Sandi A. Kwee, Hamamatsu/Queen’s PET Imaging Center 1301 Punchbowl St. Honolulu HI 96813 USAMarc N. Coel, Hamamatsu/Queen’s PET Imaging Center 1301 Punchbowl St. Honolulu HI 96813 USABevan H. Ly, University of Hawaii Department of Medicine, John A....
Source: Annals of Nuclear Medicine - June 16, 2009 Category: Radiology Tags: Annals of Nuclear Medicine Source Type: journals

FOCUS On FOCIS: Combined Chemo-Immunotherapy For The Treatment Of Hormone-Refractory Metastatic Prostate CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
UroToday.com - The long-term goal of the Tumor Immunology and Immunotherapy group at The Institute of Immunology, Charles University, 2nd Medical School is the development of dendritic cell-based cancer vaccine. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 15, 2009 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Editorial CommentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this preliminary study the authors report that denosumab, a human antibody against RANKL, normalized the increased uNTx levels more frequently than continuous BP administration in patients with prostate cancer with bone metastases previously treated with BP. They also indicate that the incidence of SRE was reduced in the denosumab group compared to the control group despite the fact that the numbers were too small to be statistically significant. Although this report is informative, the characteristics of the enrolled patients were not well illustrated. Prostate specific antigen levels which reflect the severity of the ...
Source: The Journal of Urology - June 14, 2009 Category: Urology & Nephrology Authors: Hidenori Kawashima Tags: Oncology: Prostate/Testis/Penis/Urethra Source Type: journals

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer modelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, coadministration of continuous and intermittent lonafarnib enhanced the antitumor activity of docetaxel in a panel of prostate cancer models. An intermittent dosing schedule of lonafarnib coadministered with docetaxel may allow enhanced efficacy to that of continuous dosing by improving the tolerability of higher doses of lonafarnib. © 2009 UICC (Source: International Journal of Cancer)
Source: International Journal of Cancer - June 14, 2009 Category: Cancer & Oncology Authors: Gongjie Liu, Stacey A. Taylor, Cindy H. Marrinan, Yunsheng Hsieh, W. Robert Bishop, Paul Kirschmeier, Brian J. Long Source Type: journals

ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To investigate the expression of 'ADAM metallopeptidase with thrombospondin type I motif, 1' (ADAMTS1) in human prostate cancer, and to study its relationship to microvessel density (MVD) and metastasis. ADAMTS1 has been described as an anti-angiogenic and antitumour factor, but its function in prostate cancer is unknown. ADAMTS1 expression was evaluated by immunohistochemistry in specimens obtained by transurethral resection of the prostate from patients with hormone-naïve and hormone-refractory prostate tumours, including adjacent benign tissue. A semiquantitative scoring system was used for evaluating the staining. MVD...
Source: BJU International - June 11, 2009 Category: Urology & Nephrology Authors: Heléne Gustavsson, Wanzhong Wang, Karin Jennbacken, Karin Welén, Jan-Erik Damber Source Type: journals

Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in JapanEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To evaluate the clinical results of radiotherapy (RT) for patients with regionally localized hormone-refractory prostate carcinoma (HRPC). As part of a Patterns of Care Study in Japan, a nationwide survey was conducted of RT for patients with prostate adenocarcinoma. We reviewed the detailed information of 140 patients with regionally localized HRPC who received RT between 1996 and 1998, and between 1999 and 2001, in 117 randomly selected institutes in Japan. The median (range) age of the patients was 74 (51[ndash]94) years, and their tumours were defined as well (14), moderately (51) or poorly (54) differentiated, or of u...
Source: BJU International - June 11, 2009 Category: Urology & Nephrology Authors: Tomonari Sasaki, Katsumasa Nakamura, Kazuhiko Ogawa, Hiroshi Onishi, Atsushi Okamoto, Masahiko Koizumi, Yoshiyuki Shioyama, Michihide Mitsumori, Teruki Teshima Source Type: journals

Growth kinetics and transplantation of human retinal progenitor cells.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, we have determined the growth kinetics of hRPCs and have shown that cells from donor tissue of 16-18 weeks G.A. exhibit the best proliferative dynamics under the specified conditions, and that hRPCs can also be differentiated along the photoreceptor lineage. Further, we have also demonstrated that following transplantation, some of these cells integrate within the host retina and differentiate to express rhodopsin, thereby supporting the potential utility of hRPC transplantation in the setting of retinal degenerative disorders. PMID: 19524569 [PubMed - as supplied by publisher] (Source: Experimental Eye Research)
Source: Experimental Eye Research - June 11, 2009 Category: Opthalmology Authors: Aftab U, Jiang C, Tucker B, Kim JY, Klassen H, Miljan E, Sinden J, Young M Tags: Exp Eye Res Source Type: journals

Good localized hormone-refractory prostate cancer control with EBRTEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For clinically localized hormone-refractory prostate cancer, external beam radiotherapy has a good local control rates, with nadir prostate-specific antigen levels predicting outcomes, say Japanese scientists. (Source: MedWire News - Prostate Cancer)
Source: MedWire News - Prostate Cancer - June 9, 2009 Category: Cancer & Oncology Source Type: news

[Patients with metastatic hormone-refractory prostate cancer : Second-line chemotherapy with mitoxantrone plus prednisone.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Presently, we see the indication for MP as being second-line chemotherapy in docetaxel-refractory patients with mHRPC who cannot be included in phase II/III studies. Even with only a moderate rate of partial PSA remission, every second patient had an improvement in tumor-related pain. Progression-free survival was prolonged, and the side effects of MP were comparatively low. PMID: 19513599 [PubMed - as supplied by publisher] (Source: Der Urologe. Ausg. A)
Source: Der Urologe. Ausg. A - June 4, 2009 Category: Urology & Nephrology Authors: Thomas C, Hadaschik BA, Thüroff JW, Wiesner C Tags: Urologe A Source Type: journals

Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New treatment approaches are needed for hormone refractory prostate cancer. Oncolytic adenoviruses are promising anti-cancer agents, and their efficacy can be improved by combining with conventional therapies such as ionizing radiation. The aim of this study was to determine the timing of oncolytic adenovirus treatment with regard to radiation and study the mechanisms of synergy in combination treatment. Prostate cancer cells were infected with oncolytic adenoviruses, irradiated and synergy mechanisms were assessed. In vivo models of combination treatment were tested. Radiation and oncolytic viruses were synergistic when v...
Source: International Journal of Cancer - June 1, 2009 Category: Cancer & Oncology Authors: Maria Rajecki, Taija af Hällström, Tanja Hakkarainen, Petri Nokisalmi, Sampsa Hautaniemi, Anni I. Nieminen, Mikko Tenhunen, Ville Rantanen, Reneé A. Desmond, Dung-Tsa Chen, Kilian Guse, Ulf-HÅkan Stenman, Ricardo Gargini, Mika Kapanen, Juha Klefström Source Type: journals

Percutaneous Tumor Ablation: Microencapsulated Echo-guided Interstitial Chemotherapy Combined with Cryosurgery Increases Necrosis in Prostate Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study aimed at confirming the increased growth inhibition (GI) of human prostate tumors produced by a intentionally palliative combination treatment of cryochemotherapy, i.e., partial cryoablation (CA) followed by intratumor partial chemotherapy with injection of microencapsulated 5-fluorouracil (MCC/5FU) at the ice ball (IB) periphery. We report the local effectiveness of cryochemotherapy compared to chemotherapy only with using multiple injections of MCC/5FU spaced out to maximize cumulative effect of sustained release of 5-fluorouracil (5FU) during a 21-day period. Prostate bioluminescent tumor cells - DU145 Luc+ -...
Source: Technology in Cancer Research and Treatment - May 31, 2009 Category: Cancer & Oncology Authors: Le Pivert PJ, Morrison DR, Haddad RS, Renard M, Aller A, Titus K, Doulat J Tags: Technol Cancer Res Treat Source Type: journals